Wilson's diasease
Conditions
Interventions
2:Zinc gluconate
1:Gandouling
Sponsors
The First Affiliated Hospital of Anhui University of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
15 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Comply with the diagnosis of hepatolenticular degeneration "Guidelines for Diagnosis and Treatment of Hepatolenticular Degeneration 2021"; the diagnosis of TCM syndromes complies with the syndrome of phlegm and blood stasis; Other copper-removing drugs; (3) Patients who have been treated with complexing agents for copper-removing treatment can enter the study after a 2-week washout period; (4) Age =15 years; (5) Informed consent of patients or legal representatives, And sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Severe cerebral WD patients: obvious torsion spasm, dysphagia, or bed rest and other severe neurological impairment will interfere with the safety of the subjects (UWDRS Part I neurological function score =156 points); (2) Severe liver Type WD patients: Decompensated liver cirrhosis or liver cancer, manifested as portal hypertension, ascites, splenomegaly (WBC<3.0*109/L, PLT<50*1012/L), esophageal varices, gastrointestinal bleeding, Moderate to severe anemia or hepatic encephalopathy; severe liver fibrosis shown by imaging or any laboratory abnormality (UWDRS liver function score = 17 points); (3) moderate to severe depression, recent suicidal thoughts or behavior, Severe psychiatric symptoms (UWDRS Part III Psychiatric Symptom Score = 54 points); (4) History of epileptic seizures within 6 months; (5) Complicated with serious diseases such as brain tumors, brain trauma, blood diseases, Cardiogenic diseases, HIV, etc.; (6) Nephritis, nephrotic syndrome, or kidney disease stage 3 or more; (7) Pregnant, planned pregnancy or breastfeeding women; (8) Cognitive dysfunction MMSE=26 points; (9) Those who are currently participating in other clinical trials; (10) Cannot comply with the follow-up plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Wilson disease rating scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Wilson disease overall evaluation scale;Quality of life score (PDQ-39); | — |
Countries
China
Contacts
Public ContactYang Wenming
Outcome results
None listed